



Telix Pharmaceuticals Limited
ACN 616 620 369
Suite 401, 55 Flemington Road
North Melbourne
Victoria, 3051
Australia

Telix Pharmaceuticals and Mauna Kea Technologies Launch Urologic Oncology Alliance

Melbourne (Australia) and Paris (France) – 16th December 2020. Telix Pharmaceuticals Limited (ASX: TLX, 'Telix', the 'Company') announces today it has entered an exclusive scientific and clinical research collaboration with Paris-based Mauna Kea Technologies ('Mauna Kea'), a leading medical device company pioneering the development of real-time intra-operative endoscopic visualisation of cancer tissue. The parties will work together to develop advanced image-guided surgical technologies in the field of urologic oncology.

The focus of the collaboration, which has been named the "Imaging and Robotics in Surgery" ('IRiS') Alliance, is to combine the use of Telix's dual-modality positron emission tomography ('PET') tracers that deliver concurrent PET and fluorescent (optical) imaging, with Mauna Kea's Cellvizio[®] confocal laser endomicroscopy (CLE) *in vivo* cellular imaging platform. The clinical objective is to enable the urologic surgeon to access real-time visualisation of cancer tissues in the operating theatre in a manner that can be directly correlated to pre-operative PET imaging. The IRiS Alliance aims to develop advanced capabilities for pre-operative planning, intra-operative guidance, surgical margin assessment and other surgical parameters, with initial applications in prostate and renal (kidney) cancer.

Telix CEO Dr. Christian Behrenbruch said, "The cutting-edge techniques our respective companies have developed in molecular targeting and real-time *in vivo* cellular imaging have a natural synergy and we are delighted to have formalised this ground-breaking partnership. Through the IRiS Alliance, Telix and Mauna Kea together aim to deliver significant improvements in surgical techniques and clinical outcomes in patients with urologic malignancies, with the ultimate objective of improving the lives of the patients we serve."

Mauna Kea Technologies CEO Robert L. Gershon stated, "We are excited to announce this exclusive scientific and clinical research collaboration with Telix in the field of urologic oncology. The IRiS Alliance endeavors to combine the strengths of Telix's molecular targeting with Cellvizio's real-time *in vivo* cellular imaging to bring dual-modality molecular imaging to the operating theatre for the first time. The IRiS Alliance aims to significantly transform how the urologic surgeon will evaluate, target, excise, and confirm surgical margins at the cellular level. Our collaboration will further empower surgeons to fight cancers and save lives."

About Telix Pharmaceuticals Limited

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com.

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time *in vivo* microscopic visualization. The Company's flagship product, Cellvizio[®], has received

clearance/approval in a wide range of applications in more than 40 countries, including the United States, Europe, Japan, and China. For more information on Mauna Kea Technologies, visit www.maunakeatech.com.

Telix Corporate Contact

Dr. Christian Behrenbruch
Telix Pharmaceuticals Limited
CEO
Email: chris@telixpharma.com

Telix Investor Relations

Dr. David N. Cade
Telix Pharmaceuticals Limited
CBO and Head of Investor Relations
Email: david.cade@telixpharma.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "U.S. Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.